Gemphire Therapeutics Inc. (GEMP): Cormorant Asset Management Reports New Stake

Page 1 of 8

According to a new 13G filing with the Securities and Exchange Commission, Bihua Chen‘s Cormorant Asset Management owns 900,000 shares of Gemphire Therapeutics Inc. (NASDAQ:GEMP), which amass 9.7% of the company’s outstanding stock. Gemphire Therapeutics represents a new addition to Cormorant Asset Management’s portfolio.

Gemphire Therapeutics is a clinical-stage biopharmaceutical company engaged in discovering and producing therapeutics to help treat people suffering from dyslipidemia. The company started trading on August 8 and since then its stock has gained 8.7%.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research

RAJ CREATIONZS / shutterstock.com

There are no other funds in our database with a known long position in Gemphire Therapeutics Inc. (NASDAQ:GEMP) at this time.

Follow Neurobo Pharmaceuticals Inc. (NASDAQ:NRBO)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Cormorant Global Healthcare Master Fund 0 748,350 0 748,350 748,350 8.1%
Cormorant Global Healthcare GP 0 748,350 0 748,350 748,350 8.1%
Cormorant Asset Management 0 900,000 0 900,000 900,000 9.7%
Bihua Chen 0 900,000 0 900,000 900,000 9.7%

Follow Bihua Chen's Cormorant Asset Management

Page 1 of 8 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. ___)*
Gemphire Therapeutics Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
36870A108
(CUSIP Number)
August 5, 2016
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ]            Rule 13d-1(b)
[x]            Rule 13d-1(c)
[ ]            Rule 13d-1(d)
___________________________________
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 8